David M Routman
Overview
Explore the profile of David M Routman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ali M, Riviere-Cazaux C, Johnson S, Salvatori R, Penheiter A, Smadbeck J, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 40019927
Purpose: Monitoring disease progression in patients with high-grade gliomas (HGGs) is challenging due to treatment-related changes on imaging and the requirement for neurosurgical intervention to obtain diagnostic tissue. DNA junctions...
2.
Bartemes K, Moore R, Novotny B, Pavelko K, Sherman W, Rivera M, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39964349
Background: Tumor-infiltrating lymphocytes (TILs) are associated with decreased risk of recurrence in human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC). The composition and spatial distribution of TILs and tumor-infiltrating immune cells...
3.
Vasudevan S, Candelo E, Sharifi A, Ma D, Patel S, Routman D, et al.
Head Neck
. 2025 Jan;
47(4):1291-1305.
PMID: 39853705
Background: In sinonasal cancer (SNC), treatment with proton therapy (PT) provides excellent local control, especially after gross total resection. Because of the heterogeneity and rarity of this disease site, a...
4.
Calcano G, Rourk K, Routman D, OByrne J, Chintakuntlawar A, Garcia J, et al.
Otolaryngol Head Neck Surg
. 2025 Jan;
PMID: 39764676
Objective: Margin distance is a significant prognosticator in oral cavity cancer but its role in HPV-related oropharyngeal squamous cell carcinoma [HPV(+)OPSCC] remains unclear. Here, we investigate the impact of margin...
5.
Riviere-Cazaux C, Dong X, Mo W, Kumar R, Dai C, Carlstrom L, et al.
Clin Cancer Res
. 2024 Dec;
31(5):881-889.
PMID: 39715486
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients...
6.
Nakkireddy S, Jang I, Kim M, Yin L, Rivera M, Garcia J, et al.
Commun Med (Lond)
. 2024 Oct;
4(1):190.
PMID: 39363031
Background: Deep learning techniques excel at identifying tumor-infiltrating lymphocytes (TILs) and immune phenotypes in hematoxylin and eosin (H&E)-stained slides. However, their ability to elucidate detailed functional characteristics of diverse cellular...
7.
Hernandez-Herrera G, Calcano G, Nagelschneider A, Routman D, Van Abel K
Surg Oncol Clin N Am
. 2024 Sep;
33(4):617-649.
PMID: 39244284
Several imaging modalities are utilized in the diagnosis, treatment, and surveillance of head and neck cancer. First-line imaging remains computed tomography (CT); however, MRI, PET with CT (PET/CT), and ultrasound...
8.
Armstrong M, Burkett B, OByrne T, Gottlich H, Yin L, Tasche K, et al.
JAMA Otolaryngol Head Neck Surg
. 2024 Aug;
150(12):1078-1086.
PMID: 39207815
Importance: Asymmetric oropharynx uptake on positron emission tomography (PET)/computed tomography (CT) is a common incidental finding and often prompts otolaryngology referral to rule out malignancy; however, the true risk of...
9.
Frechette K, Breen W, Brown P, Sener U, Webb L, Routman D, et al.
Biomedicines
. 2024 Aug;
12(8).
PMID: 39200256
Leptomeningeal disease (LMD) is a devastating sequelae of metastatic spread that affects approximately 5% of cancer patients. The incidence of LMD is increasing due to advancements in systemic therapy and...
10.
Hanna G, Jabalee J, Lukens J, Sun L, Rettig E, Ferrandino 2nd R, et al.
Oral Oncol
. 2024 Aug;
158:107002.
PMID: 39159525
Background: Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Testing for plasma tumor tissue modified viral (TTMV)-HPV DNA has emerged as a biomarker strategy for post-treatment...